Treatment of combat-related traumatic chronic osteomyelitis with tigecycline: a case series

Authors

  • Jamal Ahmad Wadi Office 11, The Medical Center, Jordan Hospital and medical Center 29 Adeeb Wahbeh Street Amman - Jordan 11118
  • Yaseen Alastal
  • Hasan Tayyem
  • Moh’d J. Al-Humaidi

Keywords:

Combat-related, chronic osteomyelitis, multidrug resistant gram-negative bacteria, tigecycline, clinical improvement

Abstract

Objective: To evaluate the efficacy of tigecycline treatment in Combat-Related Traumatic Chronic Osteomyelitis (CRTCO).

Methods: A retrospective study evaluated tigecycline in the treatment of CRTCO. Cases were reviewed for patients who were treated for the period 2011 - June 2012. During the tigecycline treatment period, orthopedic surgeon taking care of patients started tigecycline treatment upon their discretion, not knowing about the pending study

Results: Ten cases were included (one female), mean age 45.5 years. Most common involved bones with CRTCO were femur followed by tibia. Microbiological diagnoses were obtained mostly from bone biopsies and bone swabs. Microorganisms isolated were Acinetobacter spp. (6), Klebsiella pneumoniae (6), Escherichia coli (5), Pseudomonas aeruginosa (4), Enterococcus spp. (3), Staphylococcus aureus (1). Tigecycline mean duration of treatment was 35.7 days (range 21 - 91). Patients were treated with other antimicrobials earlier to tigecycline for a mean duration of 467.37 days (range 2 - 1825). Reasons for switching to tigecycline were: Clinical failure in all patients, in addition to side effects and microbiological failure of previous regimen. Paired difference of the ESR for eight available patients’ pair was not significant (p = 0.055), the same was for CRP (p = 0.9). Clinically improved patients were seven cases (70%).

Conclusion: CRTCO is a polymicrobial infection mostly caused by gram-negative bacilli. The outcome of treating these infections with tigecycline is promising.

Author Biography

Jamal Ahmad Wadi, Office 11, The Medical Center, Jordan Hospital and medical Center 29 Adeeb Wahbeh Street Amman - Jordan 11118

Chairman, The Infection Prevention and Control Committee

Al Khalidi Medical Center

References

- Jon T. Mader et al. Evaluation of New Anti-Infective Drugs for the Treatment of Osteomyelitis in Adults. Clinical Infectious Diseases 1992; 15(Suppll): S155-61.

- Jamal Wadi et al. Vertebral Osteomyelitis; Methods for Diagnosis and Means of Treatment. Journal of the Royal Medical Services 2011June ; 18(2): 43-48.

- Jim S. Wu, et al. Imaging-Guided Bone Biopsy for Osteomyelitis: Are There Factors Associated with Positive or Negative Cultures? American Journal of Roentgenology. June 2007 ; 188(6) 1529-1534 . doi:10.2214/AJR.06.1286AJR

- Heather C. Yun, Joanna G. Branstetter, and Clinton K. Murray. Osteomyelitis in Military Personnel Wounded in Iraq and Afghanistan. J Trauma. 2008; 64:S163–S168.

- Murphy, Richard A. et al. Multidrug-Resistant Chronic Osteomyelitis Complicating War Injury in Iraqi Civilians; Brief Report. Journal of Trauma-Injury Infection & Critical Care: July 2011; 71(1), pp 252-254. doi: 10.1097/TA.0b013e31821b8622

- Nathalie Dunkel, et al. Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-center experience. International Orthopedics. 35(11); 1725-1731. DOI: 10.1007/s00264-011-1221-y.

- Jonathan Agner Forsberg, et al. Diagnosis and Management of Chronic infection. Journal of the American Academy of Orthopaedic Surgeons. 2011 February; 19(suppl 1) S8-S19

- Brad Spellberg and Benjamin A. Lipsky. Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults. Clinical Infectious Diseases 2011 December. DOI: 10.1093/cid/cir842

- G. Euba, et al. Long-Term Follow-Up Trial of Oral Rifampin-Cotrimoxazole Combination versus Intravenous Cloxacillin in Treatment of Chronic Staphylococcal Osteomyelitis. Antimicrob Agents Chemother 2009, 53(6):2672. DOI: 10.1128/AAC.01504-08.

- Alison K. Meagher, et al. The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline. Clinical Infectious Diseases 2005; 41:S333–40.

- Stephen H. Zinner. Overview of Antibiotic Use and Resistance: Setting the Stage for Tigecycline. Clinical Infectious Diseases 2005; 41:S289–92.

- Cristina Tanaseanu, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagnostic Microbiology & Infectious Disease; July 2008: 6(3), Pages 329-338,

- Timothy Babinchak, et al., for the Tigecycline 301and 306 Study Groups. The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra-Abdominal Infections: Analysis of Pooled Clinical Trial Data. Clinical Infectious Diseases 2005; 41:S354–66.

- E. J. Ellis-Grosse, et al., for the Tigecycline 300 and 305 cSSSI Study Groups. The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin-Structure Infections: Results of 2 Double-Blind Phase 3 Comparison Studies with Vancomycin-Aztreonam. Clinical Infectious Diseases 2005; 41:S341–53.

- Li-Yan Yin et al. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. Journal of Antimicrobial Chemotherapy 2005; 55: 995–1002

- Kyle Petersen et al. Trauma-related Infections in Battlefield Casualties From Iraq. Ann Surg 2007;245: 803–811.

- Daniel P. Crane et al. Efficacy of Colistin Impregnated Beads to Prevent Multi-drug Resistant A. baumannii Implant-Associated Osteomyelitis. J Orthop Res. 2009 August; 27(8): 1008–1015. doi:10.1002/jor.20847.

- Murray, Clinton K. et al. Prevention of Infections Associated with Combat-related Extremity Injuries. Journal of Trauma-Injury Infection & Critical Care; 2011 August: 71(2); S235-S257. doi: 10.1097/TA.0b013e318227ac5f

Downloads

Additional Files

Published

2013-10-19

Issue

Vol. 3 No. 3 (2013)

Section

Articles

License

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Articles are published Under License of Creative Commons Attribution 3.0 License ©

 

Copyright policies & self-archiving

This is our Copyright Policy. We are a RoMEO green journal.

Author's Pre-print: green tick  author can archive pre-print (ie pre-refereeing)
Author's Post-print: green tick  author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: green tick  author can archive publisher's version/PDF